Notice of Allowability	Application No.	Applicant(s)
	10/780,250	SINGH ET AL.
	Examiner	Art Unit
	Ginny Portner	1645
The MAILING DATE of this communication appears on the cover sheet with the correspondence address All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS. This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.		
1. This communication is responsive to 8/31/06.		
2. The allowed claim(s) is/are 7, 26-28 now claims 1-4.		
 Acknowledgment is made of a claim for foreign priority un a)	been received. been received in Application No cuments have been received in this n of this communication to file a reply of ENT of this application.	national stage application from the complying with the requirements
4. A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.		
5. CORRECTED DRAWINGS (as "replacement sheets") must be submitted.		
(a) I including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached		
1) hereto or 2) to Paper No./Mail Date		
(b) ☐ including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date		
Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).		
6. DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.		
Attachment(s) 1. ☐ Notice of References Cited (PTO-892) 2. ☐ Notice of Draftperson's Patent Drawing Review (PTO-948) 3. ☐ Information Disclosure Statements (PTO/SB/08), Paper No./Mail Date 4. ☐ Examiner's Comment Regarding Requirement for Deposit of Biological Material	7. 🛛 Examiner's Amendm	PTO-413), e <u>attached herewith</u>

EXAMINER'S AMENDMENT

1. An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Ms. Cynthia Soumoff (Applicant's Representative) on August 31, 2006.

The application has been amended as follows:

Please cancel claims 1-6 and 8-25.

Please substitute amended claim 7 as follows:

(Currently amended) An isolated polynucleotide encoding a recombinant protein which is useful for inhibiting anthrax toxin, the recombinant protein comprising SEQ ID NO 1.

Please add the following new claims:

26. (New) An isolated DNA vector comprising the polynucleotide of claim 7.

321. (New) An isolated transformed host cell comprising the polynucleotide of claim 7.

28. (New) An isolated protein comprising SEQ ID NO 1, produced by the expression of the polynucleotide of claim 7.

2. The following is an examiner's statement of reasons for allowance: The chimeric recombinant protein comprising SEQ ID NO 1 and polynucleotide the encodes a recombinant

Application/Control Number: 10/780,250

Art Unit: 1645

protein comprising SEQ ID No 1, is not taught nor reasonably suggested by the prior art of record. The chimera being the specific insertion of a portion of Clostridium perfringens iota toxin into the anthrax toxin sequence; the combination having been found to be able to inhibit anthrax toxin binding to its receptor.

Page 3

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Ginny Portner whose telephone number is (571) 272-0862. The examiner can normally be reached on flextime, but usually M-F, alternate Fridays off.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Lynette Smith can be reached on (571) 272-0864. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Vgp August 31, 2006

> SpE TC 1600